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Introduction
Type 2 diabetes is a multifactorial disease character-
ised by chronic hyperglycaemia resulting from defects
in insulin secretion and⁄or insulin action (1,2).
These defects impact the utilisation of glucose and
free fatty acids (FFA) by muscle, liver and adipose
tissue. Factors that inﬂuence the development of
chronic hyperglycaemia include genetic abnormali-
ties; environmental causes, such as nutritional excess
and lack of activity; increased hepatic production of
glucose; increases in visceral fat; atherogenic dyslipi-
daemias; increased adiposity of muscle and liver;
b-cell dysfunction; and, an imbalance of oxidation and
inﬂammation, natural processes involved in main-
taining a physiologic state. Long-term complications
associated with chronic hyperglycaemia include
microvascular disease, such as retinopathy, nephrop-
athy, neuropathy and macrovascular diseases, includ-
ing fatal and non-fatal myocardial infarction,
peripheral vascular disease and stroke (1,2).
Understanding pathophysiologic processes that
trigger the development of type 2 diabetes mellitus
(DM2) provides opportunities for designing pharma-
cologic interventions to target mediators of these
processes. The goal of intervention is to improve
short-term glucose metabolism, as measured by fast-
ing and postprandial blood glucose levels; maintain
long-term glycaemic control, as measured by reduc-
tion in haemoglobin A1C (A1C); and, provide long-
term cardiovascular (CV) beneﬁts. Early detection,
intervention, and aggressive, long-term treatment of
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SUMMARY
Type 2 diabetes is a result of derangement of homeostatic systems of metabolic
control and immune defense. Increases in visceral fat and organ adipose, environ-
mental factors and genetic predisposition create imbalances of these homeostatic
mechanisms, ultimately leading to a condition in which the oxidative environment
cannot be held in check. A signiﬁcant imbalance between the production of reac-
tive oxygen species and antioxidant defenses, a condition called to oxidative stress,
ensues, leading to alterations in stress-signalling pathways and potentially end-
organ damage. Oxidative stress and metabolic inﬂammation upregulate the expres-
sion pro-inﬂammatory cytokines, including tissue necrosis factor alpha, monocyte
chemoattractant protein-1 and interleukin-6, as well as activating stress-sensitive
kinases, such as c-Jun N-terminal kinase (JNK), phosphokinase C isoforms, mito-
gen-activated protein kinase and inhibitor of kappa B kinase. The JNK pathway
(speciﬁcally JNK-1) appears to be a regulator that triggers the oxidative-inﬂamma-
tion cascade that, if left unchecked, can become chronic and cause abnormal glu-
cose metabolism. This can lead to insulin resistance and dysfunction of the
vasculature and pancreatic b-cell. The series of events set in motion by the interac-
tion between metabolic inﬂammation and oxidative stress constitutes an ‘oxidative-
inﬂammatory cascade’, a delicate balance driven by mediators of the immune and
metabolic systems, maintained through a positive feedback loop. Modulating an
oxidative-inﬂammation cascade may improve glucose metabolism, insulin resistance
and vascular function, thereby slowing the development and progression to cardio-
vascular diseases and type 2 diabetes.
Review Criteria
• This is not an exhaustive review but highlights
key research papers that discuss mediators of
inﬂammation and oxidative stress.
• Medline and PubMed searched for terms:
inﬂammation, oxidative stress, redox signalling,
TNF-alpha, cardiovascular, metabolism, immunity,
adhesion molecules, macrophage and insulin
resistance (combinations used and key papers
selected).
Message for the Clinic
Treatments that modulate mediators of the
oxidation-inﬂammation cascade may represent
strategies for improving glucose metabolism, insulin
resistance, vascular function and pancreatic b-cell
dysfunction. Increases in small-dense low-density
lipoprotein cholesterol, triglycerides, leucocyte
count, platelet count, fasting and postprandial
blood glucose levels, serum insulin concentrations,
visceral adiposity and C-reactive protein represent
clinical expressions of effects of mediators of
inﬂammation and oxidative stress. Increases in
systolic and ⁄ or diastolic blood pressure are also
signs.
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associated complications and improve the manage-
ment and outcome of this disease. But what are
some of the early clinical signs that may alert health-
care practitioners a patient may be at risk for devel-
oping diabetes? The amount of physical activity and
their nutritional habits are two. Low physical activity
and excessive nutrition lead to visceral adiposity,
which can be related to negative outcomes. Other
clinical signs can be more subtle, not as individual
measures, but as a total clinical picture of impending
pathophysiology. Laboratory results showing
increases of small-dense low-density lipoprotein cho-
lesterol (sdLDL-C), triglycerides, leucocyte count,
platelet count, fasting and postprandial blood glucose
levels, serum insulin concentrations and C-reactive
protein (CRP) represent clinical expressions of the
effects of mediators of inﬂammation and oxidative
stress. Elevations of systolic and diastolic blood pres-
sure elevations can also be signs.
This article is an introduction to the pathophysio-
logic consequences of inﬂammation and oxidative
stress. Discussions will address how various media-
tors of inﬂammation and oxidative stress inﬂuence
the development of insulin resistance, dysfunction of
the vasculature and pancreatic b-cell dysfunction,
and progression to DM2, and clinical signs that can
be monitored to possibly provide early detection of
these conditions.
Mediators of inﬂammation
Chronic inﬂammation associated with the metabolic
and immune systems involves a network of cellular
and systemic responses that integrate many complex
signalling pathways (3). Mediators of these pathways
include major stress hormones, noradrenaline and
adrenaline and cortisol; angiotensin-II (ang-II); pro-
inﬂammatory cytokines [e.g. tissue necrosis factor-a
(TNF-a), interleukin (IL)-6 and IL-1b]; FFA, which
enter the circulation as a result of lipolysis of adipose
tissue; and, oxidised lipids (4). Each is an important
regulator of pathways involving endocrine systems,
metabolism and immune function, as well as being
crucial components of tissue repair (2,5).
Environmental factors plus a genetic predisposi-
tion can increase adiposity, which is associated with
both a localised and systemic chronic inﬂammation
characterised by inﬁltration of inﬂammatory cells in
adipose tissue, abnormal pro-inﬂammatory cytokine
production and an increase in acute-phase reactants,
such as CRP. This phenomenon, referred to as meta-
inﬂammation (metabolic inﬂammation) (6), links
homeostatic systems of metabolic control and
immune defense, which have been highly preserved
throughout evolution in numerous organisms and
species. Increases in visceral fat and adiposity in tar-
get organs and the associated meta-inﬂammation
create an imbalance of homeostatic mechanisms that
attempt to maintain a physiologic state.
Mediators of oxidative stress
Oxidative stress is deﬁned as a signiﬁcant imbalance
between the production of reactive oxygen species
(ROS) and antioxidant defenses. It leads to altera-
tions in signalling pathways and to potential tissue
damage (7,8). Generated as by-products of normal
aerobic metabolism, ROS are metabolites of molecu-
lar oxygen (O2). They include unstable oxygen radi-
cals, including superoxide radical (
·O2
)), nitric oxide
radical (
·NO), hydroxyl radical (
·HO
)) and non-radi-
cals, such as hydrogen peroxide (H2O2), peroxyni-
trite (ONOO
)) (9,10). In an attempt to neutralise
oxidative stress, cells utilise antioxidant defenses that
are comprised of enzymatic and non-enzymatic com-
pounds that determine redox balance (6). Enzymes
include superoxide dismutase, catalase, thioredoxin,
and glutathione peroxidase, and non-enzymatic com-
pounds include glutathione, ascorbate and a-tocoph-
erol (9,10) (see Figure 1).
Meta-inﬂammation and oxidative stress are inte-
grally involved through the modulation and media-
tion of pro-inﬂammatory cytokines and ROS.
Although usually regarded as toxic by-products of
metabolism, ROS can serve as signalling functions
involved in physiologic processes (11). For example,
short-term exposures to low levels of ROS trigger
activation of speciﬁc pathways, which can result in
insulinomimetic effects (12). However, chronic expo-
sure to ROS results in an imbalance of these effects,
leading to the increased production of mediators that
drive stress-signalling pathways and cause potential
tissue damage of key target organs, such as the vas-
culature and pancreas (6). These effects can be mea-
sured by increases in systolic and diastolic blood
pressure and blood glucose levels.
Sources of oxidative stress
Increases in circulating FFA and hyperglycaemia,
chief characteristics of DM2, can both lead to leakage
of
·O2
) from the mitochondrial respiration process
and activation of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, a membrane-bound
enzyme (13,14). NADPH oxidase, a major source of
·O2
) generation, is found in a variety of cells, includ-
ing adipocytes, vascular smooth muscle cells
(VSMC), endothelial cells, ﬁbroblasts and mono-
cytes⁄macrophages (15). The immune system is also
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and neutrophil granulocytes have the capacity to
consume O2 and generate
·O2
), and require NADPH
oxidase to do so (14). The phagocytic oxidase pro-
duces several orders of magnitude of more
·O2
) than
does the NADPH oxidase from other cell types such
as endothelial cells, VSMC and adipocytes (16).
Overproduction of
·O2
) appears to be the ﬁrst and
key event in the activation of other pathways and
systems (e.g. immune and metabolic) involved in the
pathogenesis of vascular dysfunction.
Oxidative-inﬂammatory cascade
Under conditions of health, cellular processes
associated with oxidation and inﬂammation function
as compensatory⁄homeostatic mechanisms that
maintain a physiologic balance. However, when one
mechanism chronically overwhelms the other, as may
occur with environmental and⁄or endogenous stres-
sors, the balance is shifted and the outcome can be
detrimental (17). We propose the series of events set
in motion by the interaction of inﬂammation and
oxidative stress that leads to disease be referred to as
the ‘oxidative-inﬂammatory cascade (OIC)’. The OIC
is a delicate balance modulated by mediators of the
immune and metabolic systems and maintained
through a positive feedback loop (18).
Within this cascade, ROS from the immune sys-
tem, adipose tissue and mitochondria mediate⁄acti-
vate stress-sensitive kinases, such as c-Jun N-terminal
kinase (JNK), protein kinase C (PKC) isoforms,
mitogen-activated protein kinase (p38-MAPK) and
inhibitor of kappa B kinase (IKK-b). These kinases
activate the expression of pro-inﬂammatory media-
tors, such as TNF-a, IL-6 and monocyte chemoattr-
actant protein-1 (MCP-1). The action of TNF-a,
MCP-1 and IL-6, locally and⁄or systemically, further
induces the production of ROS, thus potentiating the
positive feedback loop (see Figure 2) (18).
Activation of PKC by glucose has been implicated
in the regulation and activation of membrane-associ-
ated NADPH-dependent oxidases and subsequent
production of
·O2
), whereas activation of IKK-b ulti-
mately leads to the generation of nuclear factor kB
(NF-kB), an important transcription factor that
controls NADPH oxidase, numerous inﬂammatory
cytokines and ultimately adhesion molecules, such as
intracellular adhesion molecule-1 (ICAM-1) and vas-
cular cell adhesion molecule-1 (VCAM-1) (19). These
adhesion molecules are ROS dependent and facilitate
the attraction, adhesion and inﬁltration of white
blood cells into sites of inﬂammation and the forma-
tion of vascular dysfunction (20). In a retrospective
evaluation, individuals with diabetes tended to have
higher leucocyte counts, irrespective of body mass
Figure 1 A combination of nutritional excess and physical inactivity, enhanced by a genetic predisposition, can lead to
chronic hyperglycaemia, which can increase adiposity in target organs and NADPH oxidase, leading to increases in various
reactive oxygen species (ROS). With a signiﬁcant overproduction of ROS and a decrease in production of cellular
antioxidant defenses, oxidative stress ensues.
·O2
), superoxide radical;
·NO, nitric oxide radical;
·HO
), hydroxyl radical;
H2O2, hydrogen peroxide; ONOO
), peroxynitrite; NADPH, nicotinamide adenine dinucleotide phosphate
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by ICAM-1 and VCAM-1 reactions and other media-
tors may be a clinical indicator of inﬂammation and
oxidative stress.
Inﬂuence of OIC on the development
of insulin resistance
Insulin resistance is an early event in the onset, and
plays a critical role in the development of DM2
(22,23). Physiologically, insulin binds to its receptor
on the cell surface of insulin sensitive tissues, such as
muscle, liver and adipose tissue, and activates various
insulin signalling pathways through tyrosine phos-
phorylation of the insulin receptor substrate (IRS)
proteins. The pathophysiology of IR involves the
same complex network of insulin signalling path-
ways; however, attenuation of insulin’s effect in tar-
get tissues (skeletal muscle, fat and liver) occurs (24).
A clinical sign of IR is an increase in serum insulin
levels.
Reactive oxygen species can damage cellular DNA,
membranes, lipids, and proteins, and drive inﬂam-
matory gene expression that inhibits metabolic path-
ways induced by insulin, leading to IR. Although
numerous stress-sensitive kinases⁄pathways contrib-
ute to ROS generation, the JNK pathway (speciﬁcally
JNK-1) appears to be a regulator of IR (14,25)
through increased serine phosphorylation of IRS-1
and subsequent decrease in insulin-stimulated tyro-
sine phosphorylation of IRS-1. This mechanism is
also believed to be the molecular basis of TNF-a-
induced IR (26), leading one to conclude TNF-a-
induced phenomena and JNK-1 activation are inter-
related. Results of a study by Solinas et al. (27) reveal
increases in mitochondrial ROS production and
apoptosis signal-regulating kinase-1 activity by TNF-
a-induced phenomena are associated with JNK-1
activation.
c-Jun N-terminal kinase-1 also appears to be a
major contributor of fat accumulation (perhaps
through decreased energy consumption) and obesity-
induced glucose intolerance, leading to chronic JNK
activation, and creating a vicious cycle that fuels the
progression to IR, vascular and b-cell dysfunction
(26). This progression leads to chronic hyperglyca-
Figure 2 Chronic hyperglycaemia, driven by nutritional excess and physical inactivity, greatly inﬂuences the positive
feedback loop that drives mediators of meta-inﬂammation and oxidative stress, such as TNF-a, MCP-1, IL-6, and reactive
oxygen species (ROS). These activate stress-sensitive signalling pathways, which include JNK, PKC, p38-MAPK and IKK-b.
Activation of these pathways leads to insulin resistance and dysfunction of the b-cell dysfunction and vasculature. Insulin
resistance and b-cell dysfunction cause an increase in blood glucose levels, which can create a vicious cycle leading to
pathophysiology of target organs. If left unchecked, chronic hyperglycaemia eventually causes b-cell destruction (designated
by the dotted line), leading to the development of type 2 diabetes and cardiovascular disease (CVD). Potential areas for
therapeutic intervention (designated by *) may modulate the mediators of the oxidation-inﬂammation cascade to improve
glucose tolerance, b-cell dysfunction and vascular function, thereby slowing the development of type 2 diabetes. TNF-a,
tissue necrosis factor-a; IL-6, interleukin-6; MCP-1, monocyte chemoattractant factor-1; JNK, c-Jun N-terminal kinase;
PKC, protein kinase C; MAPK, mitogen-activated protein kinase; IKK-b, inhibitor of kappa b kinase
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mic control. Approaches to ameliorate oxidative
stress have improved IR and decreased A1C (28),
leading one to conclude oxidative stress may be intri-
cately involved in glucose metabolism.
Low-grade inﬂammation is associated with obesity
because of chronic activation of the innate immune
system (5,29). Meta-inﬂammation may be the com-
mon factor that links obesity to many of its patho-
logical sequelae, such as IR, lipid accumulation and
atherosclerosis. Experimentally, ROS is implicated in
the development of obesity-induced IR. Systemic
markers of oxidative stress are increased with adipos-
ity because of dysregulation of adipocytes (30).
Increased adiposity in target organs is associated with
an accumulation of macrophages, which are a major
source of TNF-a (31,32). Localised production of
ROS by NADPH oxidase in adipose tissue increases
oxidative stress in remote tissues, causing dysregula-
tion of adipocytes, increasing secretion of TNFa,
plasminogen-activating inhibitor-1 (PAI-1), and
MCP-1, resistin, and leptin; and, decreased secretion
of adiponectin, leading to a worsening of IR (33).
Adiponectin is a circulating adipokine from adi-
pose tissue that has salutary effects on insulin signal-
ling and vascular function that is also known to
suppress systemic and cellular ROS generation (34).
Resistin and leptin are molecules that promote lipol-
ysis and FFA ﬂuxes from adipocytes, contributing to
IR (28). Hyperglycaemia changes platelet function
through macrophage release of TNF-a and an
increase in PAI-1. PAI-1 increases platelet activation
and aggregation, which play a signiﬁcant role in the
pathophysiology underlying vascular dysfunction and
myocardial infarction.
Obesity is also associated with an increased density
of angiotensin type 1 (AT-1) receptors (14). The
causative ligand, ang-II, binds to these receptors to
augment NADPH oxidase-mediated ROS production,
leading to elevated circulating ROS levels that can
impair insulin signalling (35) and have detrimental
effects in organs, such as liver, skeletal muscle and
vasculature (24,36). Clinical sign of this effect
includes an increase in systolic and⁄or diastolic
blood pressure.
Manipulation of mediators of oxidative stress can
lead to disease modiﬁcation both short- and long-
term. In an experimental study by Warnholtz et al.
(37), blocking the effects of ang-II on AT1 receptors
not only inhibited NADPH oxidase and improved
endothelial function, but also reduced early plaque
formation. This suggests that oxidative stress plays a
central role in the early stages of atherosclerosis and
vascular dysfunction, especially when it can be blocked
at the cellular level where the process is initiated (28).
OIC and vascular dysfunction
The endothelium is a continuous layer of cells that
acts as a barrier between circulating factors, includ-
ing hyperglycaemia, increased FFA, derivatives of gly-
cation and oxidation, and cells of the arterial intima
and media (38). The vasculature is a target for injury
because oxidative stress can damage the endothelial
layer, leading to meta-inﬂammation, leucocyte and
platelet extravasation, vascular damage and athero-
sclerosis. To maintain the integrity of this barrier,
endothelial cells produce NO, adenosine and plas-
minogen activator to counter the effects of procoagu-
lant factors (e.g. ﬁbrinogen and PAI-1) (39).
Nicotinamide adenine dinucleotide phosphate oxi-
dase, along with other enzymes (e.g. lipoxygenases,
myeloperoxidase, inducible nitric oxide synthase),
has also been shown to contribute to oxidation of
LDL-C, resulting in oxidised LDL (oxLDL), although
the exact mechanism is not known (40). After mono-
cytes migrate although the endothelial layer into the
intima, they differentiate into macrophages. The
resulting in oxLDL is taken up by scavenger macro-
phage receptors on macrophages to produce oxLDL-
laden macrophages. These stimulate the production
of MCP-1 (41) that triggers further macrophag-
es⁄monocytes to migrate into the intima of arterial
walls and organs and initiate the process of foam cell
formation. Foam cells further increase the produc-
tion of MCP-1 and other chemoattractants to perpet-
uate the vicious cycle of monocyte⁄macrophage
migration, ultimately leading to oxidative stress in
the intima.
Advanced glycation products (AGE) are products
of intracellular auto-oxidation of glucose. Hyper-
glycaemia increases the production of AGE, which
can contribute to the progression of diabetic compli-
cations, such as diabetic retinopathy and nephropa-
thy (42). AGE also contributes to the OIC by
binding to speciﬁc receptors for advanced glycation
products on macrophages, increasing macrophage
production of TNF-a. This pro-inﬂammatory media-
tor activates the immune system to further increase
production of ROS, which leads to decreased bio-
availability of endothelial nitric oxide synthase
(eNOS) and subsequent impairment of endothelial-
directed vasodilation and decreased vascular compli-
ance (43,44). The end result is an increase in systolic
and⁄or diastolic blood pressure.
Impact of OIC on b-cell dysfunction
As research has shown the impact of lipids on the
progression of DM2, there has been a shift from the
traditional ‘glucocentric’ view of diabetes to include
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abnormalities in FFA metabolism may result in inap-
propriate accumulation of lipids in muscle, liver, and
b-cells. It also proposes that ectopic lipid accumula-
tion is involved in the development of IR in muscle
and liver as well as impairing b-cell function (46).
Glucotoxicity and lipotoxicity induce oxidative stress
and upregulate the TNF-a and IL-6.
Research in the past few years has linked oxidative
stress and inﬂammation to b-cell dysfunction (22,47)
resulting from chronic exposure to hyperglycaemia,
FFA or a combination of the two. This chronic expo-
sure is dependent on the activation of NF-jB and
other stress-sensitive pathways by mediators of oxi-
dative stress (48). b-cells are vulnerable to cell
destruction by oxidative stress because of: mitochon-
dria drive production of ROS through increased
NADPH oxidase activity; and, a relatively low expres-
sion of antioxidant enzymes in the b-cells (12,44,49).
c-Jun N-terminal kinase-mediated serine phos-
phorylation of IRS-1 inhibits glucose-induced insulin
production in b-cells; therefore, evidence suggests
activation of the JNK pathway is the main pathway
involved in pancreatic b-cell dysfunction found in
diabetes (50). A study of obese DM2 mice showed
that suppression of the JNK pathway restored b-cell
function and insulin sensitivity, and lead to amelio-
ration of glucose tolerance (47). One might conclude
that inhibiting the mediators of OIC that lead to
b-cell dysfunction and allow the development and
progression of DM2 may actually allow a reversal of
the disease process.
Resetting the OIC to enhance glucose
metabolism and reverse IR
Modulation of OIC mechanisms involved in meta-
bolic and immune processes can improve glucose
metabolism, insulin resistance, improve vascular
function. This mitigation may slow the development
of DM2. How might interfering with one or more of
these mediators modulate and reset the OIC, bring-
ing pathophysiologic processes back into balance?
Tissue necrosis factor-a inﬂuences actions on
endothelium, brain, b-cells, bone, muscle, and adi-
pose, and drives production of ROS through interac-
tion with macrophages and mitochondria; therefore,
it may be considered a key target when attempting
to reset the OIC balance, although IL-6 and MCP-1
are also involved. Cytokines derived from muscle
(myokines) have been shown to be involved in
protection against chronic diseases associated with
low-grade inﬂammation, and in mediating the
health-beneﬁcial effects of exercise (51). All of
these pro-inﬂammatory cytokines⁄enzymes stimulate
production of ROS and all are maintained through a
positive feedback loop.
Cytokines and ROS activate JNK, IKK-b, PKC and
perhaps other stress- and inﬂammation-activated
kinases in the pathogenesis of ROS-induced IR. As
JNK-1 deﬁciency results in reduced adiposity and
improved insulin sensitivity, this also may be a key
regulator of the OIC. Thus, all these kinases might
be attractive pharmacological targets for increasing
insulin sensitivity and resetting the OIC (52).
A key enzyme involved in the formation of ROS is
NADPH oxidase, which drives many cellular reac-
tions in VSMC, mitochondria and endothelial cells.
Depending on cell type, variations in the expression
of isoforms of NADPH oxidase can differ. For exam-
ple, phagocytic oxidase contains the speciﬁc mem-
brane-bound catalytic subunit, Nox2 (as do
endothelial cells and ﬁbroblasts), which drives the
reaction to produce
·O2
), whereas VSMC also contain
Nox1 and Nox4 (53). The regulation of Nox activity
is an active area of promising research.
Hyperglycaemia has been shown to inhibit eNOS
activity and expression in endothelial cells by increas-
ing
·O2
) production by mitochondria (54). Mitochon-
drial biogenesis in in vitro models is affected by
TNF-a through downregulation of eNOS, and treat-
ment with NO donors has been shown to reverse
these effects. Defects of NO-induced mitochondrial
biogenesis and a decreased peroxisome-proliferator-
activated receptor c co-activator 1a (PGC-1a)
expression are relevant in the pathophysiology of CV
disease linked to obesity. Therefore, several steps in
mitochondrial processes may also be considered as
targets for therapeutic intervention.
Adenosine monophosphate-activated protein
kinase (AMPK) is an enzyme that has been impli-
cated in regulating glucose uptake, FFA oxidation,
and mitochondrial biogenesis in heart, liver, and
skeletal muscle (55,56). To increase efﬁciency of
mitochondria, evidence suggests increases of AMPK
from endothelial cells promotes oxidation of fatty
acids as a source of ATP production, decreasing
the production of
·O2
) (46). Thus, this enzyme may
be a key target in modulating the balance of the
OIC.
Exercise has been shown to increases NO synthesis
through stimulation of PGC-1a, increasing oxidative
phosphorylation and mitochondrial biosynthesis, and
possibly improves glucose utilisation (57). The Dia-
betes Prevention Program study showed the combi-
nation of diet and exercise was effective in decreasing
the incidence of DM2 in patients with impaired glu-
cose tolerance compared with pharmacologic therapy
(58). One could speculate that diet and exercise in
this study population modulated regulators that
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insulin resistance and patient outcomes.
Clinical evidence
Many classes of drugs possess antioxidant activity.
These include antioxidant vitamins, such as vitamin
E, vitamin C and b-carotene; oestrogen and hor-
monal replacement therapy; and, drugs that impact
the renin-angiotensin-aldosterone system (RAAS)
[e.g. angiotensin converting enzyme (ACE), angio-
tensin II receptor blockers (ARBs)] (59).
Although evidence from preclinical studies of the
effects of antioxidant vitamin therapy has been
encouraging, results from clinical outcome studies,
such as the vitamin E arm of the HOPE Study (60),
the Heart Protection Study (61), GISSI Prevention
(62) and the Primary Prevention Project (63) failed
to show clinical beneﬁt. Explanations for this lack of
observed beneﬁt in the majority of randomised trials
include oxidant stress status of the participants and
dose and combination of vitamins administered (64).
Large prospective-controlled clinical trials utilising
hormone replacement therapy also failed to show CV
beneﬁts. These studies include HERS (65), Estrogen
Replacement and Atherosclerosis (66) and the
Women’s Health Initiative Randomised Controlled
Trial (67).
However, other large-scale studies with drugs that
possess antioxidant activity, speciﬁcally those that
impact the RAAS, have shown beneﬁt. In the ACE
inhibitor arm of HOPE Study (68), there was a 34%
reduction in the onset of new DM2. And in the LIFE
Study (69), which compared an ARB to a b-blocker,
there was a 25% in the onset on new DM2. We
hypothesise these data differ from dietary antioxidant
supplements in that blocking ROS generation at the
cellular level is apparently more efﬁcacious than
reacting to systemic ROS with a dietary reagent.
Conclusions
The series of events set in motion by the interaction
of inﬂammation and oxidative stress that lead to dis-
ease may be referred to as the OIC, a delicate balance
modulated by mediators of the immune and meta-
bolic systems and maintained through a positive feed-
back loop. Activation of stress-signalling pathways,
such as JNK-1, IKK-b, PKC and perhaps other OIC-
activated kinases, may be involved in the pathogenesis
of adiposity in target organs, vascular dysfunction, IR,
b-cell dysfunction and possibly DM2. Identiﬁcation of
the molecular basis and additional sites of action for
protection against oxidative stress-induced damage
may lead to designing a therapy that can modulate
and reset the delicate balance of the OIC. Various
clinical signs can be indicators to clinicians that path-
ophysiology is underway. These signs include CRP,
sdLDL-C, increased visceral adiposity, elevations in
systolic and diastolic blood pressure and leucocyte
count. Of course, these signs may, in and of them-
selves, not be meaningful; however, when taken in
their totality, they can alert the clinician that the
patient may be at an increased risk for a clinical event.
Early detection and intervention can possibly improve
glucose utilisation, lower the risk from hyperglycaemic
insults, delay, reverse or prevent the onset of oxidative
stress-induced insulin resistance, and provide long-
term DM2 and CV morbidity and mortality beneﬁts.
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